In the US, Europe, Australia and Canada, 2014 biotech sales totaled $123.1 billion, rising 24.3%, with each country or region accounting for 76%, 19%, 5% and 0.2% of sales, respectively. Sales of Gilead Science’s hepatitis C drugs accounted for a sizable portion of revenues in 2014; adjusting for Gilead, growth for the industry was 12%. By region, revenues totaled $93.1 billion, $24.0 billion, $5.8 billion and $260 million, growing 29.1% (12% adjusting for Gilead), 14.7%, and 9.0%, and shrinking 58.2%, respectively. Companies spent $35,387 million on R&D, an increase of 20.4%. R&D expenditures in 2014 in the US, Europe, Australia and Canada were $28.8 billion, $5.6 billion, $681 million and $260 million, increasing 22.0%, 13.6%, and 4.8%, and decreasing 3.5%, respectively. Mergers and acquisitions numbered 68 in 2014, and were valued at $49 billion. Licensing deals numbered 152 and were worth $46.8 billion.

Source: EY